Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OTLK 
OUTLOOK THERAPEUTICS INC (OTLK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: OTLK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.6
1 Year Target Price $8.6
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.39% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.57M USD | Price to earnings Ratio 0.39 | 1Y Target Price 8.6 |
Price to earnings Ratio 0.39 | 1Y Target Price 8.6 | ||
Volume (30-day avg) 6 | Beta 0.31 | 52 Weeks Range 0.87 - 9.25 | Updated Date 07/1/2025 |
52 Weeks Range 0.87 - 9.25 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -122.34% | Return on Equity (TTM) -3.65% |
Valuation
Trailing PE 0.39 | Forward PE 2.85 | Enterprise Value 94328052 | Price to Sales(TTM) 13.27 |
Enterprise Value 94328052 | Price to Sales(TTM) 13.27 | ||
Enterprise Value to Revenue 26.1 | Enterprise Value to EBITDA -4.13 | Shares Outstanding 42853700 | Shares Floating 20905158 |
Shares Outstanding 42853700 | Shares Floating 20905158 | ||
Percent Insiders 38.31 | Percent Institutions 16.81 |
Analyst Ratings
Rating 2 | Target Price 8.6 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OUTLOOK THERAPEUTICS INC
Company Overview
History and Background
Outlook Therapeutics, Inc., formerly known as Innovus Pharmaceuticals, Inc., was founded in 2003 and focuses on developing and commercializing ophthalmic products. It has gone through several strategic shifts, now concentrating on ONS-5010, an ophthalmic formulation of bevacizumab for various retinal indications.
Core Business Areas
- Ophthalmic Therapeutics: Development and commercialization of ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab, for the treatment of retinal diseases.
Leadership and Structure
The leadership team includes Russell Trenary as CEO, Mark Joseph Funari as CFO and the company has a Board of Directors overseeing strategic decisions.
Top Products and Market Share
Key Offerings
- Lytenava (ONS-5010): Lytenava (bevacizumab-vikg) is an ophthalmic formulation of bevacizumab under regulatory review for wet AMD. Its primary competition includes biologics such as aflibercept (Eylea) from Regeneron and ranibizumab (Lucentis) from Genentech (Roche). Estimated future market share will depend on FDA approval and market uptake. Revenue is currently zero as it is not yet approved, revenue will grow after commercialization.
Market Dynamics
Industry Overview
The ophthalmic therapeutics market is driven by an aging population and increasing prevalence of retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The market is competitive, with established players and emerging therapies.
Positioning
Outlook Therapeutics aims to compete in the anti-VEGF market with Lytenava, potentially offering a lower-cost alternative and a differentiated formulation. Its competitive advantage lies in the potential for reduced systemic exposure due to its ophthalmic formulation.
Total Addressable Market (TAM)
The global wet AMD market is estimated to reach billions of dollars. Outlook Therapeutics is positioned to capture a portion of this TAM with Lytenava, contingent on FDA approval and successful commercialization.
Upturn SWOT Analysis
Strengths
- Potential first FDA-approved ophthalmic bevacizumab
- Targeting a large and growing market (wet AMD)
- Specific formulation potentially reducing systemic exposure
- Orphan drug designation for certain indications offering market exclusivity
Weaknesses
- Reliance on a single product (ONS-5010/Lytenava)
- Regulatory approval uncertainty
- Competition from established anti-VEGF therapies (Eylea, Lucentis)
- Limited commercial infrastructure currently in place
- History of rejected FDA application
Opportunities
- Expansion to other retinal disease indications (DME, RVO)
- Strategic partnerships for commercialization
- Market access agreements with payers
- Geographic expansion into international markets
Threats
- Failure to obtain FDA approval
- Delayed or unfavorable reimbursement decisions
- Emergence of biosimilars or competing therapies
- Clinical trial setbacks
- Financial instability or inability to raise capital
Competitors and Market Share
Key Competitors
- REGN
- ROCHE (ROG.SW)
Competitive Landscape
Outlook Therapeutics competes with established players like Regeneron and Roche in the anti-VEGF market. Its advantage lies in its unique ophthalmic formulation, potentially offering a differentiated safety profile.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D advancements and regulatory milestones rather than revenue generation.
Future Projections: Future growth depends on successful commercialization of ONS-5010. Analyst estimates vary based on approval timelines and market penetration.
Recent Initiatives: Recent initiatives include completing clinical trials for ONS-5010, preparing regulatory submissions, and securing financing.
Summary
Outlook Therapeutics is a development-stage pharmaceutical company focused on ophthalmic treatments, specifically ONS-5010 for wet AMD. Its success hinges on securing FDA approval and effectively competing with established anti-VEGF therapies. The company's financial health depends on continuous funding. Outlook needs to address regulatory setbacks and secure its financial future, as it navigates a competitive market with established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market conditions and company-specific factors can change rapidly. All investments involve risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OUTLOOK THERAPEUTICS INC
Exchange NASDAQ | Headquaters Iselin, NJ, United States | ||
IPO Launch date 2016-05-13 | EVP, CFO, Interim CEO, Treasurer, Secretary & Director Mr. Lawrence A. Kenyon CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | |
Full time employees 23 | |||
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.